Thursday, July 19, 20184:30 – 7:00 PM EST
Spend an inspiring 10 minute ‘ideastorming’ session with the some of the most influential innovation leaders in the greater Baltimore area. To schedule a session with one of our experts, please complete the application (in addition to the event registration) at www.anchorventures.org.
Join us today as we speak with Dr. Kurt Newman from Children’s National Health System about innovations in pediatrics.
Fina Biosolutions is pleased to announce that the Serum Institute of India Private Limited (SIIPL), has completed a Phase 3 study for Pneumosil® a 10-valent pneumococcal conjugate vaccine, in which the Serum Institute indicates all primary and secondary objectives were met. Pneumosil covers over 70% of invasive pneumococcal-disease causing serotypes and employs conjugation chemistry licensed from Fina Biosolutions under a 2007 technology agreement.
Last week, the Greater Washington Partnership (the Partnership) and Business Roundtable (BRT) held an event showcasing the Capital CoLAB (Collaborative of Leaders in Academia and Business). The Capital CoLAB is an action-oriented partnership of university and business leaders across the Capital Region, from Baltimore to Richmond, who have come together to position the region as a leading global hub for innovation.
A company that makes products for science researchers has bought one of the largest contract manufacturers of viral vectors for gene therapy.
Successful Marketing and PR Strategies for Your Startup
SPEAKERS
SCHEDULE
Pre-Registration REQUIRED: RSVP by NOON, 4/3 at tinyurl.com/BHIMktgPR2019
No charge to attend
*In person attendance during the discussion is required to participate in 1:1 meeting with experts.
NIH funding is critical to improving health outcomes and reducing the societal costs of illnesses. Congress should increase the NIH budget and then maintain regular, steady increases.
A sampling of recent reports shows just how much immuno-oncology continues to grow. Last month, GrandView Research projected a more than doubling of the global cancer immunotherapy market, from the $58.1 billion it tallied in 2018, to $126.9 billion by 2026. As GEN noted when it ranked the top immuno-oncology startups in February, market projections range from $124.88 billion (Transparency Market Research) to $173 billion (Market Research Engine) by 2024.
To launch a company that might attract the investment you need to develop a promising new drug candidate or research tool you need to assemble at least two, but preferably all, of these three things: (a) intellectual property (IP), (b) proof of principle, and (c) team with some biotech experience.
Viela Bio had raised $282 million when it launched at the end of February 2018.
